Breast cancer: Role of neoadjuvant therapy

International Journal of Surgery

Volumn 7, Issue 5, 2009, Pages 416-420

  Ahmed, Muhammad Ishtiaq ^a   Lennard, T W J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Adjuvant; Axilla; Breast cancer; Chemotherapy; Endocrine; Neoadjuvant

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; EXEMESTANE; FLUOROURACIL; LETROZOLE; TAMOXIFEN; TRASTUZUMAB;

ADJUVANT THERAPY; AXILLA; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RELAPSE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; HUMAN; MASTECTOMY; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HUMANS; MASTECTOMY; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL;

EID: 70350571224     PISSN: 17439191     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijsu.2009.06.001     Document Type: Review

References (31)

1. Christian M.C., McCabe M.S., Korn E.L., Abrams J.S., Kaplan R.S., and Friedman M.A. The National Cancer Institute Audit of the National Surgical Adjuvant Breast And Bowel Project protocol B-06. N Engl J Med 333 22 (1995) 1469-1474
2. Bonadonna G., Brusamolino E., Valagussa P., et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 294 8 (1976) 405-410
3. Fisher B., Saffer E., Rudock C., Coyle J., and Gunduz N. Effect of local or systemic treatment prior to primary tumor removal on the production and response to a serum growth-stimulating factor in mice. Cancer Res 49 8 (1989) 2002-2004
4. Fisher B., Brown A., Mamounas E., et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 15 7 (1997) 2483-2493
5. Fisher B., Bryant J., Wolmark N., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16 8 (1998) 2672-2685
6. Wolmark N., Wang J., Mamounas E., Bryant J., and Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr 30 (2001) 96-102
7. Van der Hage J.A., van de Velde C.J., Julien J.P., Tubiana-Hulin M., Vandervelden C., and Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 19 22 (2001) 4224-4237
8. Gianni L., Baselga J., Eiermann W., et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 11 24 Pt. 1 (2005) 8715-8721
9. Buzdar A, Valero V, Theriault R. Pathological complete response to chemotherapy is related to hormone receptor status. In: 26th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, USA: 2003.
10. Bear H.D., Anderson S., Smith R.E., et al. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 24 13 (2006) 2019-2027
11. Gazet J.C., Ford H.T., Coombes R.C., et al. Prospective randomized trial of tamoxifen vs surgery in elderly patients with breast cancer. Eur J Surg Oncol 20 3 (1994) 207-214
12. Kenny F.S., Robertson J.F.R., Ellis I.O., Elston C.W., and Blarney R.W. Long-term follow-up of elderly patients randomized to primary tamoxifen or wedge mastectomy as initial therapy for operable breast cancer. Breast 7 6 (1998) 335-339
13. Fentiman I.S., Christiaens M.R., Paridaens R., et al. Treatment of operable breast cancer in the elderly: a randomised clinical trial EORTC 10851 comparing tamoxifen alone with modified radical mastectomy. Eur J Cancer 39 3 (2003) 309-316
14. Mustacchi G., Ceccherini R., Milani S., et al. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol 14 3 (2003) 414-420
15. Dixon J.M., Love C.D., Bellamy C.O., et al. Letrozole as primary medical therapy for locally advanced and large operable breast cancer. Breast Cancer Res Treat 66 3 (2001) 191-199
16. Eiermann W., Paepke S., Appfelstaedt J., et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol 12 11 (2001) 1527-1532
17. Smith I.E., Dowsett M., Ebbs S.R., et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the immediate preoperative anastrozole, tamoxifen, or combined with tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 23 22 (2005) 5108-5116
18. Cataliotti L., Buzdar A.U., Noguchi S., et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the pre-operative "arimidex" compared to tamoxifen (PROACT) trial. Cancer 106 10 (2006) 2095-2103
19. Miller A.R., Thomason V.E., Yeh I.T., et al. Analysis of sentinel lymph node mapping with immediate pathologic review in patients receiving preoperative chemotherapy for breast carcinoma. Ann Surg Oncol 9 3 (2002) 243-247
20. Tubiana-Hulin M., Becette V., Bieche I., et al. Exemestane as neoadjuvant hormonotherapy for locally advanced breast cancer: results of a phase II trial. Anticancer Res 27 4C (2007) 2689-2696
21. Krainick U, Astner A, Jonat W, Wallwiener D. Phase II study to define safety and efficacy of exemestane as preoperative therapy for postmenopausal patients with primary breast cancer - final results of the German Neoadjuvant Aromasin Initiative (GENARI). In: 26th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, USA; 2003.
22. Semiglazov V., Kletsel A., Zhiltzova E., et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). 2005 ASCO Annual Meeting. J Clin Oncology (2005) 2530 p. No. 16S, Part I of II (June 11 Supplement)
23. Sachelarie I., Grossbard M.L., Chadha M., Feldman S., Ghesani M., and Blum R.H. Primary systemic therapy of breast cancer. Oncologist 11 6 (2006) 574-589
24. Buzdar A.U., Ibrahim N.K., Francis D., et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 23 16 (2005) 3676-3685
25. Lazaridis G., Pentheroudakis G., and Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol (2007)
26. Mauri D., Pavlidis N., and Ioannidis J.P. Neoadjuvant versus adjuvant systemic treatment in breast cancer: a meta-analysis. J Natl Cancer Inst 97 3 (2005) 188-194
27. Schwartz G.F. Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: current update. Breast J 10 2 (2004) 85-88
28. Mamounas E.P., Brown A., Anderson S., et al. Sentinel node biopsy after neoadjuvant chemotherapy in breast cancer: results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 23 12 (2005) 2694-2702
29. Charfare H., Limongelli S., and Purushotham A.D. Neoadjuvant chemotherapy in breast cancer. Br J Surg 92 1 (2005) 14-23
30. Jones J.L., Zabicki K., Christian R.L., et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg 190 4 (2005) 517-520
31. Huang E.H., Tucker S.L., Strom E.A., et al. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 22 23 (2004) 4691-4699